New imaging study reveals how implant tames eye inflammation

NCT ID NCT04340505

Completed Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 30 uveitis patients who received a fluocinolone acetonide implant to control eye inflammation. Researchers used advanced imaging (OCT, OCTA, fluorescein angiography) to track changes in inflammation over 12 months. The goal was to see if imaging could better measure treatment response than standard exams.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fluocinolone acetonide implant
What this could lead to: If successful, this could help doctors better monitor and treat uveitis inflammation using imaging, potentially improving long-term disease control.
What could go wrong: This is a small, observational study (30 people) that looks at imaging changes, not a large trial testing a new drug. Results may not apply to all uveitis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEITIS

Contacts and locations

Locations

Cole Eye Institute Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.